Ras guanyl nucleotide-releasing proteins (RasGRPs) are activators of Ras. Previous studies have indicated the possible involvement of RasGRP1 and RasGRP4 in leukemogenesis. Here, the predominant role of RasGRP1 in T-cell leukemogenesis is clarified. Notably, increased expression of RasGRP1, but not RasGRP4, was frequently observed in human T-cell malignancies. In a mouse bone marrow transplantation model, RasGRP1 exclusively induced T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) after a shorter latency when compared with RasGRP4. Accordingly, Ba/F3 cells transduced with RasGRP1 survived longer under growth factor withdrawal or phorbol ester stimulation than those transduced with RasGRP4, presumably due to the efficient activation of Ras. Intriguingly, NOTCH1 mutations resulting in a gain of function were found in 77% of the RasGRP1-mediated mouse T-ALL samples. In addition, gain-of-function NOTCH1 mutation was found in human T-cell malignancy with elevated expression of RasGRP1. Importantly, RasGRP1 and NOTCH1 signaling cooperated in the progression of T-ALL in the murine model. The leukemogenic advantage of RasGRP1 over RasGRP4 was attenuated by the disruption of a protein kinase C phosphorylation site (RasGRP1(Thr184)) not present on RasGRP4. In conclusion, cooperation between aberrant expression of RasGRP1, a strong activator of Ras, and secondary gain-of-function mutations of NOTCH1 have an important role in T-cell leukemogenesis.
INTRODUCTION
T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) is induced by the transformation of T-cell progenitors. Cytogenic abnormalities, including chromosomal translocations/deletions, gene duplications and activating gene mutations, are involved in the pathogenesis of T-ALL. 1 According to recent studies, gainof-function NOTCH1 mutations within the heterodimerization (HD) domain and/or the proline-, glutamic acid-, serine-, and threonine-rich (PEST) domain were found in 50 --70% of human T-ALL cases. 1 --5 Similar mutations of NOTCH1 were also detected in mouse models of T-ALL. 3 --7 In addition, numerous studies 3 --5,8 --14 have delineated critical roles for oncogenic Ras in leukemogenesis, and oncogenic K-Ras and N-Ras mutations were found in 10 --15% of human T-ALL cases. 15 --21 Interestingly, secondary gain-offunction mutations of NOTCH1 cooperated with oncogenic K-Ras mutations in the progression of T-ALL. 3 --5 Accordingly, aberrant Ras signaling, in cooperation with active NOTCH1 signaling, is postulated to have an important role in T-cell leukemogenesis.
The Ras guanyl nucleotide-releasing proteins (RasGRPs) are a family of guanine --nucleotide exchange factors, with four members (RasGRP1-4), which positively regulate Ras and related small GTPases. 22, 23 RasGRPs are receptors of the second messenger diacylglycerol and its analogues, the phorbol esters. 22, 23 RasGRPs contain a Ras exchanging motif domain, a guanine --nucleotide exchange factor domain, two EF-hands and a diacylglycerol-binding C1 domain. 22, 23 RasGRP1-3 harbor a PKCcatalyzed phosphorylation site closely upstream of a guanine --nucleotide exchange factor domain, which is absent from the corresponding region of RasGRP4. 24, 25 Thus, RasGRP1-3, but not RasGRP4, is regulated by PKC-mediated phosphorylation as well as by membrane diacylglycerol. 24, 25 Recent studies have shown the expression patterns and physiological functions of RasGRPs. RasGRP1 is mainly expressed in T lymphocytes, B lymphocytes and mast cells, where it regulates signaling pathways downstream of the T-cell receptor, B-cell receptor and FceRI, respectively. 26 --30 RasGRP4 is highly expressed in myeloid cells, including mast cells, and acts downstream of c-kit in mast cells. 31 --33 In the previous study, we identified RasGRP4 using expression cloning as a gene that fully transformed IL-3-dependent HF6 cells, and demonstrated that in a mouse bone marrow transplantation (BMT) model, RasGRP4 induced acute myeloid leukemia (AML) and/or T-ALL. 34 On the other hand, it has been reported that RasGRP1 transgenic mice developed thymic lymphoma or skin tumors, 35 --37 and that RasGRP1 was a common integration site in retrovirus-induced murine T-cell lymphomas. 38 In addition, expression levels of RasGRP1 influenced the responses to a farnesyltransferase inhibitor or a MEK inhibitor in leukemia/ lymphoma cells. 39 --41 These results have indicated that both RasGRP1 and RasGRP4 are involved in leukemogenesis, but the pathophysiological significance of these findings remains unclear.
In the present study, the leukemogenic functions of RasGRP1 and RasGRP4 were compared. Aberrant expression of RasGRP1, in comparison with RasGRP4, led to the efficient induction of T-ALL by cooperating with gain-of-function NOTCH1 mutations. Consistently, RasGRP1, which contained a PKC phosphorylation site, was able to more strongly activate H-, K-, or N-Ras than RasGRP4, which lacks the PKC phosphorylation site. Given the elevated expression of RasGRP1 frequently found in T-cell malignancies, RasGRP1 may have an important role in aberrant Ras signaling contributing to T-cell leukemogenesis. Further analysis of aberrant RasGRP1 signaling, as well as active NOTCH1 signaling, will lead to increased understanding of the pathogenesis of T-cell leukemias and contribute to the development of novel therapies against T-ALL.
MATERIALS AND METHODS

Patients and samples
Patients with hematologic disease (six patients with T-ALL and seven with AML) who had been diagnosed at Hiroshima University Hospital or Wakayama Medical University between 1985 and 2011 were selected for this study. All studies were approved by the Institutional Review Board at Hiroshima University or Wakayama Medical University, and the ethics committee of the University of Tokyo (approval no. 20-10-0620 and 23-10-0727). Total RNA derived from human bone marrow, thymus and fetal thymus (Clontech, Palo Alto, CA, USA) was used as a normal control. The patients' informed consent was obtained in accordance with the Declaration of Helsinki. Identification of NOTCH1 mutations were performed as described previously.
2,17,42 NOTCH1 mutations, excluding NOTCH1 single nucleotide polymorphisms (SNPs) listed in the NCBI SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/), were identified in this study.
Retroviral vectors
Mouse RasGRP1, RasGRP4, H-Ras, K-Ras, N-Ras and M-Ras were cloned from mouse bone marrow (BM) cDNA using PCR. A RasGRP1 mutant, in which threonine 184 (T184) was replaced with alanine (A) (RasGRP1 (T184A)), was generated by two-step PCR mutagenesis. Mouse RasGRP1, RasGRP4 or RasGRP1(T184A) were tagged with a FLAG epitope at the C-terminus and subcloned into the pMYs-internal ribosome entry site (IRES)-puro r (pMYs-IP), pMYs-IRES-enhanced green fluorescent protein (pMYs-IG) or pMYs-IRES-human nerve growth factor receptor (NGFR) (pMYs-INGFR) to generate pMYs-Flag-RasGRP1/4/1(T184A)-IP, pMYs-FlagRasGRP1/4/1(T184A)-IG or pMYs-RasGRP1/4/1(T184A)-INGFR. Mouse H-Ras, K-Ras, N-Ras or M-Ras, which was tagged with a FLAG epitope at the N-terminus, was subcloned into pMYs-IRES-blasticidin r (pMYs-IB) to generate pMYs-Flag-H/K/N/M-Ras-IB. Mouse intracellular NOTCH1 (ICN1), a kind gift from S Chiba (University of Tsukuba, Ibaraki, Japan), was subcloned into pMYs-INGFR to generate pMYs-ICN1-INGFR. All constructs were verified by DNA sequencing.
Retrovirus infection was performed as described previously. 43, 44 Briefly, retroviruses were generated by transient transfection of Plat-E packaging cells with FuGENE 6 (Roche Diagnostics, Mannheim, Germany). The transduced Ba/F3 cells were subjected to drug selection with 1 mg/ml puromycin and/or 10 mg/ml blasticidin.
Cell viability assay
Cell growth/viability was estimated by quantitating luminescence, using cellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA), as described previously. 45 
Flow cytometric analysis
Briefly, cells were stained with the following phycoerythrin-conjugated antibodies (Abs): CD3, CD4, CD8, Thy-1, B220, Gr-1, CD11b (eBioscience, San Diego, CA, USA) or hNGFR (BioLegend, San Diego, CA, USA). Flow cytometric analysis was performed with a FACSCalibur (BD Biosciences, San Jose, CA, USA) equipped with CellQuest (BD Biosceinces) and FlowJo Version 7.2.4 (Tree Star, San Carlos, CA, USA). 46, 47 Real-time reverse-transcription PCR Real-time reverse-transcription PCR was performed as described previously. 46 
DNA sequencing
Sequencing for the NOTCH1 HD and PEST domain mutations in samples of T-ALL induced by aberrant expression of RasGRP1 or RasGRP4 in a murine BMT model was performed as described previously. 3 --7 Immunoblot analysis
An equal number of leukemic T cells or Ba/F3 transfectants stimulated with 10 nM PMA (Sigma-Aldrich, St Louis, MO, USA) for 10 min were lysed. Immunoblotting was performed as described previously, 46,47 using the following primary Abs: anti-Flag (M2) Ab (Sigma-Aldrich), anti-b-actin Ab, anti-ERK1/2 Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-phospho-p44/42 MAPK Ab (Cell Signaling, Beverly, MA, USA).
Mouse BMT
Mouse BMT was performed as described previously. 
Statistical analysis
Statistical analysis was calculated using the Student's t-test for independent variables. P-values o0.05 were considered statistically significant.
RESULTS
Differential expression profiles for RasGRP1 or RasGRP4 in hematopoietic malignancies
Based on previous findings that overexpression of RasGRP1 or RasGRP4 was possibly involved in the leukemogenesis of T-ALL and/or AML, 34 --36 the expression levels of these two RasGRPs were examined in samples of human hematopoietic malignancies by real-time PCR ( Figure 1b) . As previously reported, 34 RasGRP4 expression was frequently elevated in AML, whereas RasGRP4 was not overexpressed in T-ALL (Figures 1b and c) . Conversely, RasGRP1 expression was frequently elevated in T-ALL, but not AML, confirming previous results. 48, 49 (Figures 1b and c). Reciprocal expression patterns of RasGRP1 and RasGRP4 were also observed in human hematopoietic cell lines (data not shown). These results suggested a major role for aberrant expression of RasGRP1 or RasGRP4 in the pathogenesis of T-ALL or AML, respectively.
RasGRP1 induced more aggressive T-ALL than RasGRP4 in a mouse BMT model A murine BMT model was used to clarify the difference in leukemogenic potency between RasGRP1 and RasGRP4. BM mononuclear cells from Balb/c mice were infected with retroviruses harboring RasGRP1, RasGRP4 or an empty vector (pMYs-IG) and transplanted into sublethally irradiated Balb/c mice. We confirmed efficient retrovirus infection: 35 --50% of BM cells transduced with RasGRP1 or RasGRP4 and 50 --60% of the mocktransduced BM cells were positive for green fluorescent protein expression before transplantation. Mice receiving transplants of mock-transduced cells remained healthy over the observation period (n ¼ 8/8) (Figure 2a ). Similar to the C57BL/6 mice used in a previous study, 34 the Balb/c mice receiving transplants of RasGRP4-transduced cells developed T-ALL with thymoma 4 --6 months after transplantation (n ¼ 4/13) or AML with hepatosplenomegaly 6 --7 months after transplantation (n ¼ 2/13). The remaining mice showed no signs of disease during the observation period (n ¼ 7/13) (Figures 2a and b) . In contrast, all the mice receiving transplants of RasGRP1-transduced cells developed T-ALL with thymoma 3 --6 months after transplantation (Figures 2a and c (Figures 3a and b) . Immunoblot analysis confirmed comparable expression of the transduced RasGRP1 and RasGRP4 in thymoma cells (Figure 2d ). In addition, either one or two proviral integration sites, which didn't seem to influence the phenotypes of the recipient mice, were detected in most of the leukemic samples (Supplementary Table 1) . Collectively, RasGRP1 induced T-ALL after a shorter latency and with a higher penetrance in a mouse BMT model when compared with RasGRP4, indicating that RasGRP1 was more potent at inducing T-cell leukemia/lymphoma than RasGRP4.
RasGRP1 induces a greater survival advantage than RasGRP4 to Ba/F3 cells under growth factor withdrawal or phorbol ester stimulation To unravel the cellular mechanism underlying the leukemogenic advantage of RasGRP1 over RasGRP4, the growth of IL-3-dependent Ba/F3 cells transduced with RasGRP1 or RasGRP4 was compared in the presence or absence of IL-3. As shown in Supplementary Figure 1a , cell growth in the presence of IL-3 was comparable between these transfectants. However, there was a significant difference in survival of these transfectants after the withdrawal of IL-3: RasGRP1-expressing cells survived longer than RasGRP4-expressing cells, although both RasGRP1 and RasGRP4 Figure 1e) . Thus, RasGRP1 synergized more strongly with N-Ras, H-Ras and K-Ras than RasGRP4, with respect to the prevention of Ba/F3 cell apoptosis (Supplementary Figure 1e) . Therefore, the ability of RasGRP1 to induce leukemogenesis more efficiently than RasGRP4 seems to depend on the ability of RasGRP1 to more strongly activate N-, H-and K-Ras.
The advantage of RasGRP1 over RasGRP4 in T-cell leukemogenesis is dependent on the RasGRP1 PKC phosphorylation site Next, we wanted to determine whether PKC-mediated regulation of RasGRP1 was involved in the increased effect of RasGRP1 over RasGRP4 in T-cell leukemogenesis because RasGRP1, but not RasGRP4, contains a PKC phosphorylation site (T184). 24, 25 To this end, we generated a RasGRP1 mutant, RasGRP1(T184A), which could not be phosphorylated by PKC (Figure 1a) . The survival of Ba/F3 cells transduced with RasGRP1, RasGRP1(T184A) or RasGRP4 was compared under growth factor withdrawal. As expected, the substitution of T184 to A reduced the survival advantage conferred by RasGRP1 on Ba/F3 cells (Figure 4a) . Similarly, this substitution also attenuated the proliferation and survival signals induced by RasGRP1 in PMA-stimulated Ba/F3 cells. (data not shown). Moreover, RasGRP1(T184A) induced T-ALL with a lower penetrance in a mouse BMT model when compared with RasGRP1; 8 out of 11 mice died of T-ALL with thymoma, whereas the other 3 mice remained healthy during the observation period (Supplementary Figure 2 ). Leukemic T cells induced by aberrant expression of RasGRP1 or RasGRP1(T184A) exhibited no significant differences in morphological appearances or surface markers (data not shown). Notably, unlike RasGRP4, RasGRP1(T184A) did not induce myeloid leukemia. Collectively, these results indicated that the advantage of RasGRP1 over RasGRP4 in T-cell leukemogenesis depends, in part, on activation of the PKC-RasGRP1-Ras signaling axis.
Gain-of-function NOTCH1 mutations cooperated with aberrantly expressed RasGRP1 in the induction of T-ALL According to previous reports, 3 --5 oncogenic K-Ras-induced T-ALL samples harbored NOTCH1 mutations. In addition, gain-of-function NOTCH1 mutations accelerated oncogenic K-Ras-initiated T-ALL. These observations prompted us to ask whether gain-of-function NOTCH1 mutations were also involved in the progression of RasGRP1-induced T-ALL. Intriguingly, insertion or deletion mutations of NOTCH1, leading to a premature translation stop in the PEST domain, were found in 10 out of 13 samples of RasGRP1-induced T-ALL (Table 1) . These mutations are thought to stabilize intracellular NOTCH1, thus activating the NOTCH1 pathway. However, no mutations were detected in the HD domain of NOTCH1 (Table 1) . On the other hand, similar insertion mutations of NOTCH1 were also observed in two out of four samples of RasGRP4-induced T-ALL (Table 1) . No NOTCH1 mutations were detected in the two RasGRP4-induced AML1 samples analyzed (Table 1 ). These results indicated that secondary gain-of-function mutations of NOTCH1 were deeply involved in the progression of RasGRP1-and RasGRP4-mediated T-ALL. To delineate the cooperative role of gain-of-function NOTCH1 mutations and aberrant expression of RasGRP1 or RasGRP4 in T-cell leukemogenesis, we transplanted mice with BM cells transduced with ICN1 (pMYs-ICN1-IG) and RasGRP1, RasGRP4, RasGRP1(T184A) or the empty vector (pMYs-INGFR). As previously reported, 3 all the mice transplanted with BM cells expressing ICN1 died of T-ALL within 60 days after the transplant. In contrast to the phenotype of T-ALL induced by RasGRP1 alone, these mice developed hepatosplenomegaly, but not thymoma; the leukemic T cells were CD4 high CD8 high Thy-1 high (Figures 5a and b, Supplementary Figure  3 and data not shown). Remarkably, all the mice receiving BM cells expressing ICN1 with RasGRP4, RasGRP1(T184A) or RasGRP1 died of T-ALL with hepatosplenomegaly, but not thymoma, after different latency periods. Leukemic T cells of T-ALL caused by these combinations (ICN1 with RasGRPs) exhibited morphological appearances and surface markers similar to those of ICN1-induced T-ALL (Supplementary Figure 3 and data not shown) . Importantly, ICN1 with RasGRP4 or RasGRP1(T184A) induced T-ALL within 40 days after transplant, whereas ICN1 with RasGRP1 did so within 25 days after transplant. These results showed that aberrant RasGRP1 or RasGRP4 signaling cooperated with active NOTCH1 signaling in T-cell leukemogenesis, although the combination of aberrant RasGRP1 and active NOTCH1 signaling induced more rapid T-ALL progression (Figure 5a ). It should be noted again that RasGRP4 and RasGRP1(T184A), both of which are unable to be phosphorylated by PKC, accelerated ICN1-induced T-ALL to the same degree. Finally, the NOTCH1 mutations in human T-cell malignancies with elevated expression of RasGRP1 were examined. Although the number of the cases was limited, gain-offunction NOTCH1 mutations (HD mutations) were found in one case (Pt S949) with elevated expression of RasGRP1 (Table 2 and  Supplementary Table 2 ). Taken together, aberrant expression of RasGRP1 cooperated with secondary gain-of-function mutations of NOTCH1 in the efficient progression of T-ALL.
DISCUSSION
Gain-of-function NOTCH1 mutations, which are highly prevalent in human T-ALL, have an essential role in T-cell leukemogenesis. According to Chiang et al., 3 these NOTCH1 mutations are divided into two groups: strong and weak gain-of-function mutations. The formers are uncommon gene alterations, generating a truncated form of NOTCH1, which alone induces T-ALL in mice. In contrast, HD and PEST domain mutations, commonly found in human T-ALL, are weak gain-of-function mutations, which fail to efficiently induce T-ALL in mice by themselves. These results indicate that weak gain-of-function NOTCH1 mutations require additional signaling aberrations, which cooperate to efficiently induce T-ALL. One such candidate is aberrant Ras signaling, because a variety of gene alterations that affect Ras signaling are found in T-lineage malignancies, including oncogenic N-Ras and KRas mutations, inactivation of the NF1 and PTEN tumor suppressors, chromosomal translocations involving the ABL and JAK2 kinases or gain-of-function JAK1 mutations. 1,15 --21,50 In addition, weak gain-of-function NOTCH1 mutations are reported to accelerate the onset of T-ALL initiated by oncogenic K-Ras mutations. 3 --5 In the present study, aberrant expression of RasGRP1 was additionally shown to cooperate with gain-offunction NOTCH1 mutations in T-cell leukemogenesis.
Although previous studies have indicated the possible involvement of RasGRP1 and RasGRP4 in leukemogenesis, 34 --36 it was difficult to compare the leukemogenic potential of these two RasGRPs because they had been evaluated in different mouse models: RasGRP1 was examined in a transgenic mouse model 35, 36 and RasGRP4 was examined in a transplantation model 34 using BM cells transduced with RasGRP4. Comparative analysis of RasGRP1 and RasGRP4, using a BMT model, showed that RasGRP1 was superior to RasGRP4 in the ability to induce T-ALL; RasGRP1 exclusively induced T-ALL after a shorter latency, whereas RasGRP4 induced T-ALL or AML, with a low penetrance. RasGRP1 was also able to more strongly activate H-, K-or N-Ras, thereby increasing cell survival more strongly than RasGRP4. The underlying molecular mechanism was, in part, due to a structural difference between RasGRP1 and RasGRP4; RasGRP1, but not RasGRP4, contains a PKC phosphorylation site. 24, 25 In fact, the disruption of the PKC phosphorylation site of RasGRP1 abrogated the in vivo leukemogenic advantage, as well as the in vitro cell survival advantage, of RasGRP1 over RasGRP4. Because PKC-mediated regulation of RasGRPs (RasGRP1 and RasGRP3) connects PKC signaling to Ras signaling in lymphocytes, 24, 25 these results implicated the activation of the PKC-RasGRP1-Ras axis in T-cell leukemogenesis. On the other hand, it should be noted that RasGRP1(T184A) did not induce myeloid leukemia at all in a BMT model, whereas RasGRP4 did, albeit with a low penetrance, which suggests a specialized role for RasGRP4 in the development of myeloid progenitor cells. One possible explanation is that RasGRP4 might strongly activate GTPases other than Ras that are involved in myeloid transformation.
Importantly, secondary frame-shift mutations of NOTCH1, which generate a premature stop codon in the PEST domain and lead to the enhanced NOTCH1 signaling, were frequently found in T-ALL induced by RasGRP1 or RasGRP4 in the BMT model. In addition, aberrant expression of RasGRP1 or RasGRP4 further accelerated the progression of T-ALL induced by ICN1, a strong gain-offunction mutation of NOTCH1, demonstrating the cooperative effect of NOTCH1 and RasGRP1 or RasGRP4 signaling on T-cell leukemogenesis. The finding that ICN1 alone or with RasGRPs induced T-ALL not involving thymoma supports the hypothesis that gain-of-function NOTCH1 mutations are secondary events occurring in the thymus in RasGRPs-induced T-ALL. In addition, analysis of human samples indicated a predominant significance of RasGRP1 in T-cell leukemogenesis. Elevated expression of RasGRP1, but not RasGRP4, was frequently found in human T-lineage malignancies, and weak gain-of-function mutations of NOTCH1 were detected in T-lineage malignancy with elevated expression of RasGRP1, although the sample size was small. Taken together, aberrant expression of RasGRP1 cooperates with secondary weak gain-of-function mutations of NOTCH1 in the progression of T-lineage malignancies.
The molecular mechanism of RasGRP1 upregulation in T-lineage malignancies remains elusive, but transcriptional regulation, posttranscriptional regulation mediated by microRNA or epigenetic regulation may be involved. According to a recent study 4 on retrovirus-mediated insertional mutagenesis using Mx1-Cre, Kras G12D mice, aberrant Ikaros expression due to retroviral integration is a frequent early event, and somatic NOTCH1 mutations arise later and cooperate with oncogenic K-Ras in T-cell leukemogenesis. Therefore, it is interesting to speculate that initiating events, such as aberrant Ikaros expression, are followed by upregulation of RasGRP1, which in turn precedes secondary NOTCH1 mutations in T-cell leukemogeneis. Further examination will be required to completely understand the pathophysiological role of RasGRP1 in leukemogenesis.
In conclusion, aberrant expression of RasGRP1, a strong activator of Ras, cooperates with secondary NOTCH1 mutations in T-cell leukemogenesis. These results suggest that combination therapies targeting both RasGRP1 and NOTCH1 signaling will be effective against most T-lineage malignancies.
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